Zai Lab has introduced a new drug called repotrectinib to help patients with advanced solid tumours that have specific gene mutations (NTRK gene fusions) and have already been treated with other targeted therapies.
Repotrectinib is a special type of medicine called a tyrosine kinase inhibitor (TKI). It is designed to target two specific genetic abnormalities called ROS1 and NTRK gene fusions, which are often found in certain types of advanced solid tumours, including non-small cell lung cancer (NSCLC). When patients with these gene fusions are treated with existing targeted therapies, they sometimes develop resistance to the treatment, and their disease continues to progress.
NTRK gene fusions are genetic changes that drive the growth of tumours in a small percentage of patients with various advanced solid tumours. Unfortunately, there are currently no approved targeted therapies available for these patients who have already been treated with TKIs.
In China, repotrectinib has received designations from the National Medical Products Administration (NMPA) for different groups of patients with ROS1-positive metastatic NSCLC.
Repotrectinib is a new medicine that targets specific genetic abnormalities in advanced solid tumours. It is particularly beneficial for patients who have already tried other treatments and have limited options.
